A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
一项随机、开放标签、多中心、活性对照的II期研究，比较改良制剂醋酸阿比特龙片（II）与原研醋酸阿比特龙在转移性去势抵抗性前列腺癌患者中的疗效。
期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04053-7
Lu, Xiaolin; Dai, Tao; Chen, Xue; Wu, Bin; Chen, Hui; Wu, Jitao; Yu, Dexin; Ge, Huixin; Li, Jian; Huang, Houbao; Fan, Tiwu; Cheng, Linzhong; Zhang, Xiaoping; Zhang, Xuepei; Yao, Xin; Wei, Junli; Xu, Zhenqiang; Yang, Wenzeng; He, Chaohong; Luo, Jiexin; Guan, Ling; Fu, Bin; Wang, Qilin; Chen, Xiaofeng; Zhang, Yongdong; Shi, Benkang; Zheng, Bin; Wang, Yong; Luo, Hong; Chen, Guoqiang; Wang, Huan; Wang, Quanren; Ye, Dingwei
